Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-programmed death-1) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) Meeting Abstract

  

Authors:	Sznol, M.; Kluger, H.; Callahan, M. K.; Postow, M. A.; Gordon, R.; Seal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; Burke, M. M.; Ralabate, A.; Rivera, A.; Kronenberg, S. A.; Agunwamba, B. U.; Feely, W.; Quan, H.; Krishnan, S.; Gupta, A.; Wolchok, J. D.
Abstract Title:	Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-programmed death-1) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
Meeting Title:	COSA's 41st Annual Scientific Meeting
Journal Title:	Asia-Pacific Journal of Clinical Oncology
Volume:	10
Issue:	Suppl.8
Meeting Dates:	2014 Dec 2-4
Meeting Location:	Melbourne, Australia
ISSN:	1743-7555
Publisher:	Wiley Blackwell
Date Published:	2014-12-01
Start Page:	188
Language:	English
ACCESSION:	WOS:000345350900337
PROVIDER:	wos
PUBMED:	25409571
DOI:	10.1111/ajco.12305
Notes:	Meeting Abstract: 412 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/66307